Prednisone Administration in Quiescent COPD Patients to Determine the Effect on Gene Expression
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
In this study, prednisone dose, day/time administration will be controlled in a stable COPD
patient population to determine its effect on peripheral whole blood gene expression. This
data has never been collected in a COPD population using the investigators' chosen platform
for gene expression (Affymetrix Human Gene 1.1 ST). Conducting this experiment is essential
for achieving the broader aims of an already existing and related study titled "Clinical
Implementation and Outcomes Evaluation of Blood-Based Biomarkers for COPD Management" study.
As part of this existing study, blood is being collected from hospitalized and
non-hospitalized COPD patients in order to develop a blood-based biomarker test for the
diagnosis and prediction of acute exacerbation of COPD (AECOPD). The majority of these
patients were administered prednisone as part of standard care for the treatment of AECOPD.
As such, the effect of prednisone on gene expression needs to be ruled out.